Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole versus Jorveza for eosinophilic oesophagitis
ACTRN12623000604606Phase 4Completed
- Sponsor
- Northern Adelaide Local Health Network
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in eosinophilic esophagitis (EoE) comparing Pantoprazole first with Jorveza first (2 arms). Primary endpoints: Histologic remission at 8 weeks and Histologic remission at 16 weeks. Started Dec 2023; status: completed.
02
Drugs
pantoprazolebudesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on ACTRN12623000604606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000604606.